Changing schizophrenia treatment landscape

CE

Promise in the Changing Landscape of Schizophrenia Treatment

Nurses: 1.50 Nursing contact hours, including 1.50 hours of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Released: December 17, 2024

Expiration: December 16, 2025

Joseph P. McEvoy
Joseph P. McEvoy, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

The novel antipsychotic mechanism of xanomeline-trospium involves:

2.

In clinical trials of olanzapine/samidorphan, what was the key differentiating safety outcome compared to olanzapine alone?

3.

The phase 3 EMERGENT trials of xanomeline-trospium demonstrated which efficacy outcome?

4.

Which of the following novel agents is being explored to improve cognitive impairment associated with schizophrenia (CIAS) through modulation of the glycine transporter?

5.

When initiating xanomeline-trospium, the recommended titration approach is:

6.

How knowledgeable do you feel about the safety, efficacy, and clinical use of new medications with novel mechanisms of action for the treatment of schizophrenia?​